Sort
40,608 grants matching “prostate cancer”
Proteomic Predictors of Clinical Outcome of Targeted Therapies in Prostate Cancer
$1,088,432David B Agus · Stanford University · U54 · FY2010 · CA
DNA Sequencing
$1,088,205Trevor K Archer · National Institute Of Environmental Health Sciences · ZIC · FY2013 · ES
The Howard University SCORE Program Supplemental Grant
$1,088,173Howard University · S06 · FY2003 · GM
Center for Interventional Oncology
$1,087,597Bradford J Wood · Division Of Basic Sciences - Nci · ZID · FY2017 · CA
Center for Interventional Oncology
$1,086,388Bradford J Wood · Division Of Basic Sciences - Nci · ZID · FY2024 · CA
ROLES OF LIN28B IN NEUROENDOCRINE PROSTATE CANCER
$1,086,342The University Of British Columbia · · FY2020 · Defense Health Agency
AN INTEGRATED GENOMIC DEFINITION AND THERAPEUTIC STRATEGY FOR ANDROGEN-INDIFFERENT PROSTATE CANCERS.
$1,086,307The Univeristy Of Texas M.D. Anderson Cancer Center · · FY2022 · Department of the Army
Mechanisms of Normal Tissue Toxicity
$1,085,592Deborah Citrin · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Signal Transduction Events and the Regulation of Cell Growth
$1,085,526Jane B Trepel · Division Of Clinical Sciences - Nci · ZIC · FY2023 · CA
Scalable single-cell workflow for multiomic analyses of chromatin interactions, accessibility, gene expression and cell surface proteins to unravel mechanisms of cellular diversity
$1,084,321Anthony Schmitt · Arima Genomics, Inc. · R44 · FY2024 · GM
Discovery and verification of novel biomarkers of colorectal cancer recurrence
$1,084,138Christopher I Li · Fred Hutchinson Cancer Research Center · R01 · FY2015 · CA
Ultrasound Ablation on Bone Cancer Under CT Fluoroscopy
$1,083,824Everette C Burdette · Acoustic Medsystems, Inc. · R44 · FY2010 · CA
Precision Interception of Aggressive Prostate Cancer in African American Men
$1,083,300Timothy R Rebbeck · Dana-Farber Cancer Inst · P20 · FY2018 · CA
(PQC-5) Zwitterionic NIR/Zr-89 Agents for Prostate Cancer Staging and Treatment
$1,082,023John V Frangioni · Curadel, Llc · R01 · FY2014 · CA
PRMT5/MEP50 AS A CRITICAL EPIGENETIC REGULATOR AND THERAPEUTIC TARGET FOR THERAPY-INDUCED NEUROENDOCRINE PROSTATE CANCER
$1,081,246Purdue University · · FY2022 · Defense Health Agency
The Role of the Integrated Stress Response in Cancer
$1,080,107Constantinos Koumenis · University Of Pennsylvania · P01 · FY2020 · CA
DCTD Screening Technologies
$1,080,000Larry Arthur · Leidos Biomedical Research, Inc. · N01 · FY2010 · CA
The HARVARD UROLOGIC RESEARCH CENTER
$1,079,958Children'S Hospital Boston · P50 · FY2005 · DK
The HARVARD UROLOGIC RESEARCH CENTER
$1,079,958Children'S Hospital Boston · P50 · FY2003 · DK
The HARVARD UROLOGIC RESEARCH CENTER
$1,079,958Children'S Hospital Boston · P50 · FY2004 · DK
NOVEL APPROACH TO IMPROVING PROSTATE CANCER SCREENING AMONG AFRICAN AMERICAN MEN
$1,079,899Weill Medical College Of Cornell University · · FY2022 · Defense Health Agency
Photodynamic Therapy - Basic Science Studies
$1,078,951Fred W Hetzel · University Of Colorado Denver · P01 · FY2008 · CA
PROSTATE CANCER CLINICAL TRIALS CONSORTIUM: CLINICAL RESEARCH SITE APPLICATION
$1,078,411Regents Of The University Of California, San Francisco, The · · FY2015 · Department of the Army
Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
$1,078,239Lance L Yokochi · Pacific Health Research Institute · N01 · FY2009 · CA
ELK-1 TARGETED MOLECULES AS A NEW PARADIGM FOR PROSTATE CANCER TREATMENT
$1,077,998Wayne State University · · FY2017 · Department of the Army